Why the study?
Does adjuvant chemotherapy with high-dose methotrexate and doxorubicin reduce the number and delay the appearance of pulmonary metastases in patients with osteogenic sarcoma?
Population
48 patients with osteogenic sarcoma (15 in the adjuvant group, 33 age- and sex-matched controls)
Comparison
Adjuvant chemotherapy with high-dose… vs Age- and sex-matched controls
Design
Cohort
Authors
Loading...
Adjuvant chemotherapy was associated with delayed and fewer metastases in osteogenic sarcoma; leaves open survival benefit and need for randomized confirmation.
Does adjuvant chemotherapy with high-dose methotrexate and doxorubicin reduce the number and delay the appearance of pulmonary metastases in patients with osteogenic sarcoma?
Adjuvant chemotherapy with high-dose methotrexate and doxorubicin significantly delays the appearance and reduces the number of pulmonary metastases in patients with osteogenic sarcoma.
Jaffe et al. (1983) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: